Pharmaceutical Executive, May 1, 2011 - Pharmaceutical Executive

ADVERTISEMENT

Pharmaceutical Executive, May 1, 2011
Features
Out of Control
By Mason Tenaglia
The pharmaceutical industry needs to use new and better data to accurately measure how much it is willing to invest in avoiding plan control
12th Annual Pharm Exec 50
By Jerry Cacciotti , Patrick Clinton
Who's taken this year's top spot? Find out in Pharm Exec's annual run-down of the world's Top 50 pharma companies.
The Cloud and Beyond
By Jennifer Ringler
Cloud computing is slowly but surely becoming the IT platform of choice for the industry. Pharm Exec looks at how it now affects nearly every aspect of the pharma business.
Columns
Blame the Driver, Not the Car
By Al Topin
Why is building a successful marketing program so difficult? It should be simple, if your product is worth marketing.
Outrage Over Drug Prices
By Jill Wechsler
Stiff price tags draw scrutiny from Congress and consumers, and raise questions about FDA policies
Using Social Networks to Guide Product Spend
Online sentiment analysis monitoring can help biopharma resource managers make crucial decisions
UK Stakeholders Have Their Say on Value-Based Pricing
By Julian Upton
The UK coalition government's consultation on the intro of value-based pricing has invited caution and resistance
High-Risks to High Reward
According to Eli Lilly, managing alliances requires more than good people skills
Seeing Through the Transparency Directive
By Reflector
The EU is largely powerless when it comes to policies over pricing and reimbursement
On Tour with Merck's Robots
A factory tour to examine Merck's automated robots—and the human minds that inspire them
Expanded Liability for Generic, Brand Manufacturers Ahead?
By John Brenner
To what extent are generics companies obligated by law to request labeling changes with FDA?
iDeal Tool of Sales Trade
The sleek, portable iPad, coupled with customized apps, gives sales reps a leg up
Competition 2.0: Brands vs. Generics
By Stan Bernard, MD
Innovator and generics companies are colliding as they invade each other's turf
From the Editor
Keeping Your Place on the Nifty 50
By William Looney
What do the Pharm Exec 50 numbers tell us? The dominant theme seems to be one of gradual restructuring toward a post-patent-cliff era.
Sponsored Content
Malaysia: The Overlooked Emerging Market
By Sponsored by Focus Reports
Rising income per capita and a budding consumer health consciousness are fueling a CAGR of 9.5%, giving investors plenty of room to expand market penetration
The Elusive Single-Point-of-Entry
By Sponsored by Focus Reports
Considering Big Pharma's trade objectives, the success of regional regulatory harmonization is not insignificant

ADVERTISEMENT

Click here